See more : Dragoneer Growth Opportunities Corp. (DGNR) Income Statement Analysis – Financial Results
Complete financial analysis of Neuren Pharmaceuticals Limited (NURPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neuren Pharmaceuticals Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Minsheng Banking Corp., Ltd. (CGMBF) Income Statement Analysis – Financial Results
- TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO) Income Statement Analysis – Financial Results
- Condor Gold Plc (CNDGF) Income Statement Analysis – Financial Results
- BC Moly Ltd. (CYUXF) Income Statement Analysis – Financial Results
- StoneBridge Acquisition Corporation (APAC) Income Statement Analysis – Financial Results
Neuren Pharmaceuticals Limited (NURPF)
About Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 231.94M | 14.55M | 3.20M | 717.00K | 495.00K | 13.54M | 631.00K | 3.15M | 1.67M | 2.93M | 4.79M | 0.00 | 0.00 | 4.65M | 5.00M | 2.27M | 944.16K | 172.97K | 429.67K | 1.40M | 2.84M | 2.12M |
| Cost of Revenue | 26.75M | 10.00K | 8.00K | 6.00K | 4.00K | 77.00K | 78.00K | 80.00K | 90.00K | 10.02M | 8.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 205.19M | 14.54M | 3.19M | 711.00K | 491.00K | 13.47M | 553.00K | 3.07M | 1.58M | -7.09M | -3.86M | 0.00 | 0.00 | 4.65M | 5.00M | 2.27M | 944.16K | 172.97K | 429.67K | 1.40M | 2.84M | 2.12M |
| Gross Profit Ratio | 88.47% | 99.93% | 99.75% | 99.16% | 99.19% | 99.43% | 87.64% | 97.46% | 94.62% | -241.73% | -80.50% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 26.75M | 12.71M | 9.52M | 7.76M | 9.86M | 6.10M | 4.30M | 12.44M | 14.13M | 10.02M | 8.72M | 0.00 | 5.33M | 7.02M | 3.21M | 8.65M | 10.36M | 8.50M | 8.68M | 5.59M | 0.00 | 0.00 |
| General & Administrative | 5.95M | 3.44M | 1.91M | 1.76M | 1.71M | 2.07M | 1.89M | 2.73M | 3.12M | 2.54M | 2.97M | 2.59M | 2.43M | 1.72M | 920.35K | 1.80M | 2.47M | 2.55M | 2.22M | 1.77M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.95M | 3.44M | 1.91M | 1.76M | 1.71M | 2.07M | 1.89M | 2.73M | 3.12M | 2.54M | 2.97M | 2.59M | 2.43M | 1.72M | 920.35K | 1.80M | 2.47M | 2.55M | 2.22M | 1.77M | 0.00 | 0.00 |
| Other Expenses | 0.00 | 1.39M | 3.60M | 186.00K | 366.00K | -2.51M | 3.71M | 1.12M | 2.77M | 3.81M | 3.74M | 4.09M | 3.38M | -230.05K | 164.32K | 354.66K | 938.00K | 1.56M | 2.18M | 813.63K | -8.16M | -7.35M |
| Operating Expenses | 32.70M | 16.16M | 11.44M | 9.53M | 11.58M | 8.25M | 6.28M | 15.25M | 17.34M | 12.65M | 12.36M | 9.48M | 8.25M | 9.45M | 5.06M | 12.19M | 14.22M | 12.35M | 11.72M | 8.42M | 513.61K | 525.00K |
| Cost & Expenses | 59.45M | 16.16M | 11.44M | 9.53M | 11.58M | 8.25M | 6.28M | 15.25M | 17.34M | 12.65M | 12.36M | 9.48M | 8.25M | 9.45M | 5.06M | 12.19M | 14.22M | 12.35M | 11.72M | 8.42M | 513.61K | 525.00K |
| Interest Income | 5.69M | 391.00K | 41.00K | 147.00K | 389.00K | 218.00K | 47.00K | 188.00K | 335.00K | 561.00K | 198.55K | 200.67K | 132.37K | 39.48K | 19.43K | 129.65K | 243.09K | 501.96K | 578.18K | 9.23K | 191.62K | 295.48K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.09K | 1.52K | 2.43K | 25.93K | 60.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 17.00K | 10.00K | 8.00K | 6.00K | 4.00K | 77.00K | 78.00K | 80.00K | 90.00K | 100.00K | 428.35K | 360.88K | 353.75K | 401.64K | 505.91K | 1.12M | 889.55K | 786.38K | 820.10K | 949.94K | 513.61K | 525.00K |
| EBITDA | 199.23M | -1.60M | -8.23M | -8.80M | -11.07M | 5.89M | -6.20M | -11.94M | -15.49M | -9.63M | -6.22M | -9.12M | -4.38M | -4.59M | 481.63K | -8.31M | -11.20M | -11.39M | -9.69M | -6.58M | 2.84M | 2.12M |
| EBITDA Ratio | 85.90% | -10.97% | -357.52% | -1,328.59% | -2,337.58% | 39.64% | -982.09% | -481.49% | -1,031.20% | -427.23% | -188.17% | 0.00% | 0.00% | -98.69% | 12.73% | -365.47% | -1,186.47% | -6,586.09% | -2,436.74% | -433.60% | 100.00% | 100.00% |
| Operating Income | 172.49M | -1.61M | -11.44M | -9.53M | -11.58M | 5.29M | -6.28M | -15.25M | -17.34M | -12.62M | -9.45M | -9.48M | -4.73M | -4.99M | 131.13K | -9.43M | -12.09M | -12.18M | -11.29M | -7.02M | 2.32M | 1.60M |
| Operating Income Ratio | 74.37% | -11.04% | -357.77% | -1,329.43% | -2,338.38% | 39.07% | -994.45% | -484.03% | -1,036.58% | -430.64% | -197.11% | 0.00% | 0.00% | -107.33% | 2.62% | -414.78% | -1,280.69% | -7,040.73% | -2,627.61% | -501.46% | 81.89% | 75.25% |
| Total Other Income/Expenses | 32.65M | 13.63M | 9.96M | 7.38M | 10.12M | -2.22M | 9.56M | 1.39M | 3.20M | 11.42M | 3.54M | 4.29M | -6.09K | -1.52K | -157.84K | -5.44M | 1.12M | 2.06M | 3.00M | 1.91M | -7.97M | -7.05M |
| Income Before Tax | 205.14M | 184.00K | -7.79M | -9.19M | -10.82M | 3.07M | -2.44M | -13.86M | -14.15M | -8.32M | -11.34M | -5.19M | -4.74M | -4.99M | -26.71K | -15.36M | -12.15M | -10.12M | -8.29M | -5.69M | -5.65M | -5.46M |
| Income Before Tax Ratio | 88.44% | 1.26% | -243.79% | -1,282.15% | -2,185.05% | 22.69% | -386.53% | -439.94% | -845.55% | -283.73% | -236.47% | 0.00% | 0.00% | -107.37% | -0.53% | -675.29% | -1,287.13% | -5,848.46% | -1,929.57% | -406.79% | -199.14% | -257.29% |
| Income Tax Expense | 48.06M | -401.00K | -49.00K | -153.00K | -393.00K | -296.00K | -631.00K | -1.84M | -749.00K | -549.00K | 2.67M | -296.64K | 3.30M | -325.72K | 40.47K | 61.06K | 998.77K | -501.96K | 17.75K | -5.69M | -5.65M | -5.46M |
| Net Income | 157.08M | 184.00K | -7.79M | -9.19M | -10.82M | 3.07M | -1.81M | -12.01M | -13.40M | -8.30M | -11.30M | -5.09M | -4.65M | -4.89M | 99.56K | -15.42M | -12.15M | -10.12M | -8.31M | -5.69M | -5.65M | -5.46M |
| Net Income Ratio | 67.72% | 1.26% | -243.79% | -1,282.15% | -2,185.05% | 22.69% | -286.53% | -381.40% | -800.78% | -283.08% | -235.69% | 0.00% | 0.00% | -105.28% | 1.99% | -677.97% | -1,287.13% | -5,848.46% | -1,933.70% | -406.79% | -199.14% | -257.29% |
| EPS | 1.20 | 0.00 | -0.07 | -0.09 | -0.11 | 0.03 | -0.02 | -0.13 | -0.16 | -0.11 | -0.18 | -0.09 | -0.12 | -0.23 | 0.01 | -1.25 | -1.64 | -1.55 | -1.51 | -2.53 | -2.51 | -2.43 |
| EPS Diluted | 1.20 | 0.00 | -0.07 | -0.09 | -0.11 | 0.03 | -0.02 | -0.13 | -0.16 | -0.11 | -0.18 | -0.09 | -0.12 | -0.23 | 0.01 | -1.25 | -1.64 | -1.55 | -1.51 | -2.53 | -2.51 | -2.43 |
| Weighted Avg Shares Out | 130.79M | 125.97M | 117.77M | 107.06M | 100.17M | 99.04M | 91.96M | 89.18M | 84.02M | 77.62M | 63.06M | 58.71M | 38.24M | 21.24M | 14.97M | 12.32M | 7.39M | 6.54M | 5.50M | 2.25M | 2.25M | 2.25M |
| Weighted Avg Shares Out (Dil) | 130.77M | 128.91M | 117.77M | 107.06M | 100.17M | 99.04M | 96.46M | 89.18M | 84.02M | 77.62M | 63.06M | 58.71M | 38.24M | 21.24M | 14.97M | 12.32M | 7.39M | 6.54M | 5.50M | 2.25M | 2.25M | 2.25M |
No news found for: NURPF
Source: https://incomestatements.info
Category: Stock Reports